0001689375-24-000007.txt : 20240308
0001689375-24-000007.hdr.sgml : 20240308
20240308163426
ACCESSION NUMBER: 0001689375-24-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240306
FILED AS OF DATE: 20240308
DATE AS OF CHANGE: 20240308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dowden Nathan J
CENTRAL INDEX KEY: 0001873392
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40969
FILM NUMBER: 24734983
MAIL ADDRESS:
STREET 1: 6 TIDE STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entrada Therapeutics, Inc.
CENTRAL INDEX KEY: 0001689375
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813983399
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE DESIGN CENTER PLACE
STREET 2: SUITE 17-500
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-305-1825
MAIL ADDRESS:
STREET 1: ONE DESIGN CENTER PLACE
STREET 2: SUITE 17-500
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: CycloPorters, Inc.
DATE OF NAME CHANGE: 20161104
4
1
wk-form4_1709933649.xml
FORM 4
X0508
4
2024-03-06
0
0001689375
Entrada Therapeutics, Inc.
TRDA
0001873392
Dowden Nathan J
C/O ENTRADA THERAPEUTICS, INC.
ONE DESIGN CENTER PLACE, SUITE 17-500
BOSTON
MA
02210
0
1
0
0
President & COO
1
Common Stock
2024-03-06
4
S
0
1826
12.3213
D
137204
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.02 to $12.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jared Cohen, as Attorney-in-Fact
2024-03-08